Safety and effectiveness of post-trastuzumab deruxtecan regimens in patients with HER2-positive metastatic breast cancer who discontinued trastuzumab deruxtecan due to interstitial lung disease - PubM
3 hours ago
- #Metastatic breast cancer
- #Interstitial lung disease
- #Trastuzumab deruxtecan
- Study focused on the safety and effectiveness of treatments after trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer patients who discontinued T-DXd due to interstitial lung disease (ILD).
- Analysis included 146 patients, with ILD grades during prior T-DXd treatment ranging from 1 to 3.
- Most patients (81.5%) received subsequent anti-HER2 treatment post-T-DXd discontinuation.
- Real-world progression-free survival (rwPFS) was 7.2 months, and overall survival was 32.4 months.
- Outcomes were numerically better in patients with grade 1 ILD compared to grade 3.
- Low ILD recurrence rates were observed during subsequent treatments (3.4% in first post-T-DXd treatment, 2.2% in second).
- Findings emphasize the importance of early ILD detection and management to enable continued anti-HER2 therapy.
- Study highlights the potential benefits of subsequent anti-HER2 therapies despite prior ILD with T-DXd.